



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/990,427 | 11/14/2001 | Avi J. Ashkenazi | P2730P1C10 | 4110 |

35489 7590 11/01/2004

HELLER EHRMAN WHITE & MCAULIFFE LLP
275 MIDDLEFIELD ROAD
MENLO PARK, CO 94025-3506

EXAMINER

MURPHY, JOSEPH F

| | |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

1646

DATE MAILED: 11/01/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/990,427

Applicant(s)

ASHKENAZI ET AL.

Examiner

Joseph F Murphy

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 8/20/2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 119-123 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 119-123 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date <u>08202004</u> . | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1646

DETAILED ACTION

Formal Matters

Claims 119-123 are pending and under consideration.

Information Disclosure Statement

The Information Disclosure Statement submitted 8/20/2004 has been considered, and an initialed copy is attached.

Response to Amendment

Applicant's amendment and arguments filed 8/20/2004 have been fully considered but they are persuasive in part.

The objections to the Specification for a non-descriptive title and use of embedded hyperlinks, have been obviated by Applicant's amendment and are thus withdrawn.

Claim Rejections - 35 USC §§ 101, 112, first paragraph

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 119-123 stand rejected under 35 U.S.C. § 101 because they are drawn to an invention with no apparent or disclosed patentable utility, for reasons of record set forth in the Office Action of 4/19/2004. The instant application has provided a description of an isolated

Art Unit: 1646

DNA encoding a protein, the protein encoded thereby and antibodies to the protein. The instant application does not disclose the biological role of this protein or its significance. Applicant is directed to the Utility Examination Guidelines, Federal Register, Vol. 66, No. 4, pages 1092-1099, Friday January 5, 2001.

The data in the Specification show that gene expression is increased in tumor cell lines and primary tumors. No data is presented regarding the levels of protein expression. It does not necessarily follow that a decrease in copy number of the mRNA results in a change in protein expression that would correlate to the disease state, and thus it does not follow that an antibody to the polypeptide would correlate to the disease state. Haynes et al. (Electrophoresis 19:1862-1871, 1998) studied 80 proteins relatively homogeneous in half-life and expression level, and found no strong correlation between protein and transcript levels; for some genes, equivalent mRNA levels translated into protein abundances which varied by more than 50-fold. Haynes concluded that the protein levels couldn't be accurately predicted from the level of the corresponding mRNA transcript (page 1863, second paragraph and Figure 1).

The Specification additionally sets forth that the PRO830 is homologous to known proteins. However, it is commonly known in the art that sequence-to-function methods of assigning protein function are prone to errors (Doerks et al. 1998). These errors can be due to sequence similarity of the query region to a region of the alleged similar protein that is not the active site, as well as homologs that did not have the same catalytic activity because active site residues of the characterized family were not conserved (Doerks et al. page 248, column 3, fourth and fifth paragraphs). Inaccurate use of sequence-to-function methods have led to significant function-annotation errors in the sequence databases (Doerks et al. page 250, column

Art Unit: 1646

1, third paragraph). Furthermore, Brenner (1999, Trends in Genetics 15:132-133) argues that accurate inference of function from homology must be a difficult problem since, assuming there are only about 1000 major gene superfamilies in nature, then most homologs must have different molecular and cellular functions. Finally, Bork et al. (1996, Trends in Genetics 12:425-427) add that the software robots that assign functions to new proteins often assign a function to a whole new protein based on structural similarity of a small domain of the new protein to a small domain of a known protein. Such questionable interpretations are written into the sequence database and are then considered facts.

After complete characterization, the protein may be found to have a patentable utility, and thus an antibody that binds this protein would have a patentable utility. This further characterization, however, is part of the act of invention and until it has been undertaken Applicant's claimed invention is incomplete. The instant situation is directly analogous to that which was addressed in *Brenner v. Manson*, 148 USPQ 689 (Sup. Ct., 1966), in which a novel compound which was structurally analogous to other compounds which were known to possess anticancer activity was alleged to be potentially useful as an antitumor agent in the absence of evidence supporting this utility. The court expressed the opinion that all chemical compounds are "useful" to the chemical arts when this term is given its broadest interpretation. However, the court held that this broad interpretation was not the intended definition of "useful" as it appears in 35 USC § 101, which requires that an invention must have either an immediately obvious or fully disclosed "real world" utility. The court held that:

"The basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility", "[u]nless and until a process is refined and developed to this point-where specific benefit exists

Art Unit: 1646

in currently available form-there is insufficient justification for permitting an applicant to engross what may prove to be a broad field", and "a patent is not a hunting license", "[i]t is not a reward for the search, but compensation for its successful conclusion."

The instant claims are drawn to an antibody that binds a polypeptide which has an as yet undetermined function or biological significance. Until some actual and specific significance can be attributed to the protein identified in the specification as PRO830, the instant invention is incomplete. The polypeptide encoded by the nucleic acids of the instant invention is alleged to be structurally analogous to proteins that are known in the art as, *inter alia*, HSU88154. In the absence of knowledge of the natural substrate or biological significance of this protein, there is no immediately obvious patentable use for it. To employ an antibody that binds a protein of the instant invention in the identification of substances that inhibit the proteins activity is clearly to use it as the object of further research that has been determined by the courts to be a non-patentable utility. Since the instant specification does not disclose a "real world" use for PRO830 then the claimed invention is incomplete and, therefore, does not meet the requirements of 35 USC § 101 as being useful.

Applicant argues that the Haynes et al. publication does not support the rejection. Applicant characterizes Haynes et al. as teaching that there is a general trend but no strong correlation between protein expression level and transcript level. Applicant criticizes Haynes et al. for being directed to a study of yeast proteins. Applicant further characterizes Haynes et al.'s conclusions as showing that there is a positive correlation between transcript and protein for most of the 80 yeast proteins studied, but the correlation is not linear and thus one cannot accurately predict protein levels from mRNA levels. Applicant stresses that very few data points scattered away from the expected normal or showed a lack of correlation between mRNA and

Art Unit: 1646

protein. Applicant concludes that Haynes et al. show that it is more likely than not that a positive correlation exists between mRNA and protein levels. This has been fully considered but is not found to be persuasive. In the instant case, the specification provides data showing a very small increase in DNA copy number, approximately 2-fold, in a few tumor samples for PRO830.

There is no evidence regarding whether or not the PRO830 mRNA or protein levels are also increased in these tumor samples. Since the instant claims are directed to PRO830 protein, it was imperative to find evidence in the relevant scientific literature whether or not a small increase in DNA copy number would be considered by the skilled artisan to be predictive of increased mRNA and protein levels. Haynes et al. was cited as providing evidence that protein levels cannot be accurately predicted from mRNA levels, and that variances as much as 40-fold or even 50-fold were not uncommon (p. 1863). Haynes et al. used yeast as an art-accepted model for eukaryotic systems. Given how small the DNA copy number of PRO830 increased, and the evidence provided by Haynes et al., Pennica et al. and Konopka et al., it was clear that one skilled in the art would not assume that a small increase in gene copy number would correlate with significantly increased mRNA or protein levels. One skilled in the art would do further research to determine whether or not the PRO830 protein levels increased significantly in the tumor samples. Such further research requirements makes it clear that the asserted utility is not yet in currently available form, i.e., it is not substantial. This further experimentation is part of the act of invention and until it has been undertaken, Applicant's claimed invention is incomplete. The instant situation is directly analogous to that which was addressed in *Brenner v. Manson*, 148 U.S.P.Q. 689, cited above.

Art Unit: 1646

Applicant refers to three additional articles (Orntoft et al., Hyman et al. and Pollack et al.) as providing evidence that gene amplification generally results in elevated levels of the encoded protein. Applicant characterizes Orntoft et al. as teaching in general (18 of 23 cases) chromosomal areas with more than 2-fold gain of DNA showed a corresponding increase in mRNA transcripts. Applicant characterizes Hyman et al. as providing evidence of a prominent global influence of copy number changes on gene expression levels. Applicant characterizes Pollack et al. as teaching that 62% of highly amplified genes show moderately or highly elevated expression and that, on average, a 2-fold change in DNA copy number is associated with a 1.5-fold change in mRNA levels. This has been fully considered but is not found to be persuasive. Orntoft et al. appear to have looked at increased DNA content over large regions of chromosomes and comparing that to mRNA and protein levels from the chromosomal region. Their approach to investigating gene copy number was termed CGH. Orntoft et al. do not appear to look at gene amplification, mRNA levels and protein levels from a single gene at a time. The instant specification reports data regarding amplification of individual genes, which may or may not be in a chromosomal region which is highly amplified. Orntoft et al. concentrated on regions of chromosomes with strong gains of chromosomal material containing clusters of genes (p. 40). This analysis was not done for PRO830 in the instant specification. That is, it is not clear whether or not PRO830 is in a gene cluster in a region of a chromosome that is highly amplified. Therefore, the relevance of Orntoft et al. is not clear. Hyman et al. used the same CGH approach in their research. Less than half (44%) of highly amplified genes showed mRNA overexpression (abstract). Protein levels were not investigated. Therefore, Hyman et al. also do not support utility of the claimed proteins. Pollack et al. also used CGH technology, concentrating on large

Art Unit: 1646

chromosome regions showing high amplification (p. 12965). Pollack et al. did not investigate protein levels. Therefore, Pollack et al. also do not support the asserted utility of the claimed invention. Importantly, none of the three papers reported that the research was relevant to identifying probes that can be used as cancer diagnostics. The three papers state that the research was relevant to the development of potential cancer therapeutics, but also clearly imply that much further research was needed before such therapeutics were in readily available form. Accordingly, the specification's assertions that the claimed PRO830 proteins have utility in the fields of cancer diagnostics and cancer therapeutics are not substantial.

Applicant presents a declaration by Dr. Polakis filed with the response under 37 CFR 1.132. In the declaration, Dr. Polakis states that the primary focus of the Tumor Antigen Project was to identify tumor cell markers useful as targets for cancer diagnostics and therapeutics. Dr. Polakis states that approximately 200 gene transcripts were identified that are present in human tumor cells at significantly higher levels than in corresponding normal human cells. Dr. Polakis states that antibodies to approximately 30 of the tumor antigen proteins have been developed and used to show that approximately 80% of the samples show correlation between increased mRNA levels and changes in protein levels. Dr. Polakis states that it remains a central dogma in molecular biology that increased mRNA levels are predictive of corresponding increased levels of the encoded protein. Dr. Polakis characterizes the reports of instances where such a correlation does not exist as exceptions to the rule. This has been fully considered but is not found to be persuasive. First, it is important to note that the instant specification provides no information regarding increased mRNA levels of PRO830 in tumor samples relevant to normal samples. Only gene amplification data was presented. Therefore, the declaration is insufficient

Art Unit: 1646

to overcome the rejection of claims 58-65 and 68-70 based upon 35 U.S.C. §§ 101 and 112, first paragraph, since it is limited to a discussion of data regarding the correlation of mRNA levels and protein levels, and not gene amplification levels and protein levels. Furthermore, the declaration does not provide data such that the examiner can independently draw conclusions. Only Dr. Polakis' conclusions are provided in the declaration. There is no evidentiary support to Dr. Polakis' statement that it remains a central dogma in molecular biology that increased mRNA levels are predictive of corresponding increased levels of the encoded protein. Finally, it is noted that the literature cautions researchers from drawing conclusions based on small changes in transcript expression levels between normal and cancerous tissue. For example, Hu et al. (2003, Journal of Proteome Research 2:405-412) analyzed 2286 genes that showed a greater than 1-fold difference in mean expression level between breast cancer samples and normal samples in a microarray (p. 408, middle of right column). Hu et al. discovered that, for genes displaying a 5-fold change or less in tumors compared to normal, there was no evidence of a correlation between altered gene expression and a known role in the disease. However, among genes with a 10-fold or more change in expression level, there was a strong and significant correlation between expression level and a published role in the disease (see discussion section). In addition, Hancock states "the markers that are generated by proteomics are not always consistent with the markers that are generated from expression profiling".

Applicant further submits a Declaration filed pursuant to 37 CFR 1.132 by Dr. Ashkenazi. In the Declaration Dr. Ashkenazi states that even when amplification of a cancer marker gene does not result in significant over-expression of the corresponding gene product, this very absence of gene product over-expression still provides significant information for

Art Unit: 1646

cancer diagnosis and treatment, because if over-expression of the gene product does not parallel gene amplification in certain tumor types but does so in others, then parallel monitoring of gene amplification and gene product over-expression enables more accurate tumor classification and hence better determination of suitable therapy. The Declaration of Dr. Ashkenazi further states that the absence of over-expression is crucial information for the practicing clinician. If a gene is amplified but the corresponding gene product is not over-expressed, the clinician accordingly will decide not to treat a patient with agents that target that gene product.

However, the assertion that a difference in gene expression compared to gene amplification enables more accurate tumor classification is a conclusory statement. No evidence is provided of a tumor where this difference has aided classification, and there is further no evidence of a tumor wherein a difference in expression relative to amplification aided a clinician in ruling out potential treatment agents. Indeed, the art shows that further experimentation is necessary to determine a use for the gene of interest. Wang et al. teaches that differential display is the first of many steps required in the discovery of a novel pharmacological target, especially given that the function of the factor is most likely unknown. Therefore, further action should be taken to characterize the functions of a particular gene of interest, including ... validation for the importance of the gene in disease processes. See Wang, page 279, column 2, full paragraph 1.

For all of these reasons, the rejections are maintained.

Claims 119-123 stand rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Art Unit: 1646

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 119-120, 122-124 stand rejected under 35 U.S.C. 102(b) as being anticipated by U.S. Patent No. 5,169,933 (Anderson et al.), for reasons of record set forth in the Office Action of 4/19/2004.

The '933 patent discloses covalently linked complexes comprising antibodies to a peptide which has a region of 8 amino acids 100% identical to SEQ ID NO: 175 (see Sequence Comparison A, attached). These antibodies would cross-react to SEQ ID NO: 175, thus claims 119 and 124 are anticipated. The '933 patent also discloses monoclonal antibodies, and labeled antibodies (column 4, lines 3-11), thus claims 120, 123 are anticipated. The '933 patent also discloses antibody fragments (column 3, lines 50-53), thus claims 122 is anticipated.

Applicant has amended the claims by adding the limitation wherein the antibody specifically binds to SEQ ID NO: 175, and argues that that the claim language "specifically binds" when given its broadest reasonable interpretation consistent with the interpretation of those skilled in the art, distinguishes antibodies that bind the polypeptide of SEQ ID NO: 175 from antibodies that bind the 8 amino acid residues of the '933 polypeptide, and that therefore the rejection should be withdrawn. However, these arguments have been considered, but are not deemed persuasive. It is well-known in the art that antibodies do not bind to only one peptide. Antibodies are selective for antigens in those peptides and would be expected to bind any peptide

Art Unit: 1646

comprising that antigen. The '933 protein shares an 8 amino acid overlap with the protein of SEQ ID NO: 175. Therefore, given the art-accepted definition of "specifically binds" as well as the well-known properties of antigen-antibody binding, it would be expected, in absence of evidence to the contrary, that antibodies which bind to the protein of the '993 patent would also bind to the protein of SEQ ID NO: 175.

In further support of his position, the Examiner cites Elgert (Immunology :Understanding the Immune System, page 416, 1996). Elgert defines specific binding as "selective reactions occurring between an antigen and its corresponding antibody-combining site." This definition does not state that an antibody will bind only one protein (i.e. exclusive), but that the antibody will react with its corresponding antigen. Therefore, an antibody would be expected to bind any protein comprising that antigen.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 119-124 stand rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,169,933 (Anderson et al.) in view of U.S. Patent No. 5,530,101 (Queen et al.), for reasons of record set forth in the Office Action of 4/19/2004.

Art Unit: 1646

The disclosure of the '933 patent has been set forth above. The '933 patent differs from the instant invention by not disclosing humanized or single-chain antibodies to the polypeptide. U.S. Patent No. 5,530,101 discloses that non-human antibodies do not fix complement as well as human antibodies, thus necessitating the humanization of antibodies produced in other species (column 1, line 38), this also indicates the superiority of human antibodies. U.S. Patent No. 5,530,101 discloses the humanization of antibodies (column 2, lines 1-8). Humanized antibodies are disclosed as being important because they bind to the same antigen as the original antibodies, but are less immunogenic when injected into humans. U.S. Patent No. 5,530,101 discloses that immunoglobulins may exist in a variety of other forms, including, *inter alia*, single chains. Therefore, it would have been obvious to one of skill in the art at the time the invention was made to humanize antibodies which bind SEQ ID NO: 175.

Applicant has amended the claims by adding the limitation wherein the antibody specifically binds to SEQ ID NO: 175, and argues that that the claim language "specifically binds" when given its broadest reasonable interpretation consistent with the interpretation of those skilled in the art, distinguishes antibodies that bind the polypeptide of SEQ ID NO: 175 from antibodies that bind the 8 amino acid residues of the '933 polypeptide, and that therefore the rejection should be withdrawn. However, these arguments have been considered, but are not deemed persuasive. It is well-known in the art that antibodies do not bind to only one peptide. Antibodies are selective for antigens in those peptides and would be expected to bind any peptide comprising that antigen. The '933 protein shares an 8 amino acid overlap with the protein of SEQ ID NO: 175.

Art Unit: 1646

In further support of this position, the Examiner cites Elgert (Immunology: Understanding the Immune System, page 416, 1996). Elgert defines specific binding as “selective reactions occurring between an antigen and its corresponding antibody-combining site.” This definition does not state that an antibody will bind only one protein (i.e. exclusive), but that the antibody will react with its corresponding antigen. Therefore, given the art-accepted definition of “specifically binds” as well as the well-known properties of antigen-antibody binding, it would be expected, in absence of evidence to the contrary, that antibodies which bind to the protein of the ‘933 patent would also bind to the protein of SEQ ID NO: 175.

Conclusion

No claim is allowed.

Advisory Information


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Murphy whose telephone number is (571) 272-0877. The examiner can normally be reached Monday through Friday from 7:30 am to 5:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on (571) 272-0961.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1646

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Joseph F. Murphy, Ph. D.
Patent Examiner
Art Unit 1646
October 21, 2004


JOSEPH MURPHY
PATENT EXAMINER